Journey Medical signals positive EBITDA for remainder of 2026 as it plans to add up to 5 sales professionals
Source: SeekingAlpha
2026-05-13 19:32:15 ET
More on Journey Medical
- Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
- Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript
- Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand
- Journey Medical Non-GAAP EPS of $0.10, revenue of $61.6M misses by $3.05M
- Seeking Alpha’s Quant Rating on Journey Medical
Read the full article on Seeking Alpha
For further details see:
Journey Medical signals positive EBITDA for remainder of 2026 as it plans to add up to 5 sales professionals
Journey Medical Corporation
NASDAQ: DERM
DERM Trading
-4.35% G/L:
$4.945 Last:
148,273 Volume:
$5.15 Open:
DERM Latest News
May 19, 2026 04:45:00 pm
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
May 13, 2026 04:01:00 pm
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 06, 2026 04:01:00 pm
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
$266,218,987
14,090,816
2.7%
16
N/A
Pharmaceuticals
Healthcare
US
Scottsdale
